Literature DB >> 31954102

Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis: A Cross-Sectional Analysis of the IPF-PRO Registry.

Emily C O'Brien1, Anne S Hellkamp2, Megan L Neely2, Aparna Swaminathan2, Shaun Bender3, Laurie D Snyder2, Daniel A Culver4, Craig S Conoscenti3, Jamie L Todd2, Scott M Palmer2, Thomas B Leonard3.   

Abstract

BACKGROUND: Limited data are available on the association between clinically measured disease severity markers and quality of life (QOL) in idiopathic pulmonary fibrosis (IPF). The study examined the associations between objective disease severity metrics and QOL in a contemporary IPF population.
METHODS: This study evaluated baseline data from patients enrolled in the multicenter, US-based Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry between June 2014 and July 2018. Disease severity metrics included FVC % predicted, diffusing capacity for carbon monoxide (Dlco) % predicted, supplemental oxygen use with activity, supplemental oxygen use at rest, and two summary scores (the Gender-Age-Lung Physiology index, based on gender, age, and % predicted values for Dlco and FVC; and the Composite Physiologic Index, based on % predicted values for Dlco, FVC, and FEV1). Multivariable adjusted regression models were used to examine cross-sectional associations between each severity measure and St. George's Respiratory Questionnaire (SGRQ) total score.
RESULTS: Among 829 patients with complete SGRQ data, the median (interquartile range) SGRQ score at enrollment was 40 (26-53), with higher scores indicating worse QOL. Modest SGRQ impairments were observed with increasing Gender-Age-Lung Physiology score (2.9 [1.8-4.0] per 1-point increase] and with increasing Composite Physiologic Index scores (3.0 [2.4-3.6] per 5-point increase). Substantial SGRQ impairments were observed for oxygen use with activity (15.6 [12.9-18.2]), oxygen use at rest (16.2 [13.0-19.4]), and decreasing Dlco (5.0 [4.0-6.1] per 10% decrease in % predicted).
CONCLUSIONS: Objective measures of disease severity, including severity scores, physiologic parameters, and supplemental oxygen use, are associated with worse QOL in patients with IPF. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01915511; URL: www.clinicaltrials.gov.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  idiopathic pulmonary fibrosis; lung function; quality of life

Mesh:

Year:  2020        PMID: 31954102     DOI: 10.1016/j.chest.2019.11.042

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  7 in total

1.  The impact of idiopathic pulmonary fibrosis on health state utility values: evidence from Australia.

Authors:  E Haydn Walters; Andrew J Palmer; Ingrid A Cox; Barbara de Graaff; Hasnat Ahmed; Julie Campbell; Petr Otahal; Tamera J Corte; Ian Glaspole; Yuben Moodley; Nicole Goh; Sacha Macansh
Journal:  Qual Life Res       Date:  2021-05-17       Impact factor: 4.147

2.  Assessment of health-related quality of life in Australian patients with idiopathic pulmonary fibrosis: a comparison of the EQ-5D-5L and the AQoL-8D.

Authors:  Ingrid A Cox; Julie Campbell; Barbara de Graaff; Petr Otahal; Tamera J Corte; Yuben Moodley; Peter Hopkins; Sacha Macansh; E Haydn Walters; Andrew J Palmer
Journal:  Qual Life Res       Date:  2022-08-04       Impact factor: 3.440

3.  Factor Analyses and Validity of the Transplant Evaluation Rating Scale (TERS) in a Large Sample of Lung Transplant Candidates.

Authors:  Mariel Nöhre; Georgios Paslakis; Özgür Albayrak; Maximilian Bauer-Hohmann; Jan Brederecke; Daniela Eser-Valeri; Igor Tudorache; Martina de Zwaan
Journal:  Front Psychiatry       Date:  2020-04-30       Impact factor: 4.157

4.  Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry.

Authors:  Jing Gao; Dimitrios Kalafatis; Lisa Carlson; Ida H A Pesonen; Chuan-Xing Li; Åsa Wheelock; Jesper M Magnusson; C Magnus Sköld
Journal:  Respir Res       Date:  2021-02-05

5.  Idiopathic pulmonary fibrosis patients with severe physiologic impairment: characteristics and outcomes.

Authors:  Jean Pastre; Scott Barnett; Inga Ksovreli; Jeannie Taylor; A Whitney Brown; Oksana A Shlobin; Kareem Ahmad; Vikramjit Khangoora; Shambhu Aryal; Christopher S King; Steven D Nathan
Journal:  Respir Res       Date:  2021-01-06

6.  Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden.

Authors:  Lisa Lancaster; Francesco Bonella; Yoshikazu Inoue; Vincent Cottin; James Siddall; Mark Small; Jonathan Langley
Journal:  Respirology       Date:  2021-10-05       Impact factor: 6.175

7.  Quality of Life and Healthcare Resource Use in a Real-world Patient Population with Idiopathic Pulmonary Fibrosis: The PROOF Registry.

Authors:  Wim A Wuyts; Caroline Dahlqvist; Hans Slabbynck; Marc Schlesser; Natacha Gusbin; Christophe Compere; Sofie Maddens; Shemra Rizzo; Klaus-Uwe Kirchgaessler; Karen Bartley; Benjamin Bondue
Journal:  Pulm Ther       Date:  2022-04-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.